Navigation Links
New Acetadote® Formulation Now Available in the U.S.
Date:3/22/2011

NASHVILLE, Tenn., March 22, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that it has completed the U.S. launch of its new formulation of Acetadote® (acetylcysteine) Injection, the Company's product used to treat acetaminophen poisoning. The proprietary new formulation, which does not contain ethylene diamine tetracetic acid (EDTA) or any other stabilization or chelating agents, is now stocked at wholesalers serving hospitals across the country.

Acetadote is used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter pain relief and fever-reducing products. The new formulation was approved by the U.S. Food and Drug Administration (FDA) in January and replaces the previously marketed product. Acetaminophen continues to be the leading cause of poisonings reported by hospital emergency rooms in the United States(1), and Acetadote has become a standard of care for treating this potentially life-threatening condition.

"We are pleased to make this next generation of Acetadote available to the hospital community and the growing number of patients who will benefit from it," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "This launch marks an important milestone in our strategy to support our products by improving upon existing formulations and expanding into new patient populations."

Cumberland has worked with U.S. wholesalers to transition inventories from the original to the new formulation. Shipments of the original formulation have ceased and the Company is now filling all Acetadote orders with the new product. A communications campaign has been initiated to support poison control centers and U.S. hospital pharmacists as they transition to the new formulation, which includes an extended shelf life of 30 months, up from 24 months for the o
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
3. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
4. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
7. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
8. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
9. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
10. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
11. New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The Parenteral Drug Association (PDA) is moving ... protocols. The new initiative stems from ... industry participants and regulatory authority representatives at the PDA ... Washington, DC . Representatives of both the ... workshop. Attendees indicated openness to engaging regulators and industry ...
(Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/s6g5wm/global ) has announced the addition of ... report to their offering. ... devices have been broadly classified into wide ... are used for the treatment of different ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... -- Although there is mounting evidence that muscle-strength ... older adults in the United States don,t engage ... research. Less than one-quarter of adults over ... Department of Health and Human Services, the study ... health and fitness and staying independent, researchers advised. ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , , MONDAY, May 19 (HealthDay News) -- Findings from two ... erectile dysfunction can be a powerful early warning sign for ... men with diabetes but no signs of heart disease found ... percent more likely to have a heart attack or other ...
... of Nebraska Medical Center-led pilot study that showed antidepressants ... and neck cancer patients is the focus of an ... one of the publications produced by the Journal of ... led by UNMCs William Lydiatt, M.D., and Bill Burke, ...
... study from University Hospitals Case Medical Center (UHCMC) finds ... with malignant brain tumors are not treated as aggressively ... Furthermore, the researchers find that if patients over 75 ... and radiation, they have better survival rates. The findings ...
... have new life as a stroke treatment, researchers say. ... ways inhibiting white blood cells and enzymes that, ... vessels, respectively, says Dr. David Hess, chair of the ... School of Medicine. The broad-spectrum antibiotic also seems to ...
... May 19 Baker Energy, a unit,of Michael ... that the Wyoming,State Department of Environmental Quality (DEQ) ... (Huber), with a first-of-its-kind award,for their joint commitment ... http://www.newscom.com/cgi-bin/prnh/20061214/BAKERLOGO ), Wyoming DEQ Storm ...
... a nationwide clinical trial led by a University of ... ablation is an effective treatment for dysplasia in people ... deadly gastrointestinal cancer. , The interim results show there ... and a placebo or sham treatment, said Dr. Nicholas ...
Cached Medicine News:Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 2Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 2Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: